Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Breast Cancer Res Treat. 2015 Mar 6;150(2):309–320. doi: 10.1007/s10549-015-3324-4

Fig. 1.

Fig. 1

CCL2 expression is increased in luminal B breast cancer.

a Immunohistochemistry staining was performed for CCL2 expression in patient samples of normal breast tissue (n = 24), luminal A (n = 173) or luminal B (n = 81) breast tumor tissues.

b Immunohistochemistry staining was performed for CCL2 expression in normal mouse mammary gland (n = 11) or PyVmT mammary tumor tissues (n = 17).

c Immunohistochemistry staining was performed for CCL2 expression in normal mammary gland (n = 7) or Neu-overexpressing mammary tumor tissues (n = 7). Magnified inset shows low-level expression in normal epithelium and stromal cells. Expression was quantified by Image J. Statistical analysis was performed by One Way ANOVA with Bonferroni post hoc comparison (A) or Mann–Whitney two-sample test (B). Statistical significance was determined by p value < 0.05. *p < 0.05, ***p < 0.001. Values are shown as Mean ± SEM